Healthcare / BiotechnologyTaipei Exchange
$33.05
-0.55 (-1.64%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-69.7M · quality 62.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-15.8%
↓Gross Margin
5.3%
↓Debt/Equity
0.08
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
-11.5%
FCF CAGR
—
FCF margin
-113.2%
FCF / Net income
1.45x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $61.5M · net income $-48.1M · FCF $-69.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $61.5M | $61.5M | $64.7M | $89.0M | $88.9M |
| Net Income | $-48.1M | $-48.1M | $-64.6M | $-28.2M | $-17.2M |
| EBITDA | $-46.3M | $-46.3M | $-72.1M | $-29.5M | $-15.1M |
| EPS | -1.23 | -1.23 | -1.87 | -1.49 | -0.91 |
| Gross Margin | 5.3% | 5.3% | -14.0% | 13.2% | 21.8% |
| Operating Margin | -123.2% | -123.2% | -131.2% | -45.3% | -31.8% |
| Net Margin | -78.2% | -78.2% | -99.9% | -31.7% | -19.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.08 | 0.08 | 0.28 | 1.50 | 0.86 |
| Current Ratio | 1.25 | 1.25 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-69.7M | $-69.7M | $-75.4M | $-3.4M | $-17.2M |
| Returns | |||||
| ROE | -15.8% | -15.8% | -18.6% | -37.2% | -15.3% |
| Valuation | |||||
| P/B | 4.22 | 4.22 | 2.44 | 5.07 | 2.80 |
| Growth & Yield | |||||
| Revenue Growth | -4.9% | -4.9% | -27.2% | 0.0% | — |
| EPS Growth | 34.2% | 34.2% | -25.5% | -63.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-5.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.87 → -1.23
Residual
-5.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.